(Q33178158)

23 July 2017

Isolation, purity analysis and stability of hyperforin as a standard material from Hypericum perforatum L. (English)

1 reference

(1S,5S,7S,8R)-4-hydroxy-8-methyl-3,5,7-tris(3-methylbut-2-enyl)-8-(4-methylpent-3-enyl)-1-(2-methylpropanoyl)bicyclo[3.3.1]non-3-ene-2,9-dione

23 July 2017

1 reference

1 reference

1 reference

H C Orth

1

1 reference

PubMed ID

10217319

23 July 2017

C Rentel

series ordinal

2

1 reference

PubMed ID

10217319

23 July 2017

P C Schmidt

series ordinal

3

1 reference

23 July 2017

February 1999

1 reference

full work available at URL

16 September 2022

https://academic.oup.com/jpp/article-pdf/51/2/193/36785513/0022357991772132.pdf

1 reference

19 March 2024

https://api.unpaywall.org/v2/10.1211/0022357991772132?email=unpaywall_01@example.com

published in

Journal of Pharmacy and Pharmacology

1 reference

23 July 2017

51

1 reference

23 July 2017

193-200

1 reference

23 July 2017

2

1 reference

https://api.unpaywall.org/v2/10.1211/0022357991772132?email=unpaywall_01@example.com

23 July 2017

1 reference

19 March 2024

access restriction status

open access

1 reference

based on heuristic

inferred from online access status

cites work

Antidepressant activity of hypericum perforatum and hyperforin: the neglected possibility

1 reference

https://api.crossref.org/works/10.1211%2F0022357991772132

St. John's wort in mild to moderate depression: the relevance of hyperforin for the clinical efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357991772132

St John's wort for depression--an overview and meta-analysis of randomised clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357991772132

Hyperforin represents the neurotransmitter reuptake inhibiting constituent of hypericum extract.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357991772132

Pharmacodynamic effects of two different hypericum extracts in healthy volunteers measured by quantitative EEG.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357991772132

Inhibition of monoamine oxidase by hypericin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357991772132

Effects of the total extract and fractions of Hypericum perforatum in animal assays for antidepressant activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357991772132

Hyperforin, possibly the major non-nitrogenous secondary metabolite of Hypericum perforatum L

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357991772132

Inhibition of MAO by fractions and constituents of hypericum extract.

21 January 2018

1 reference

12 April 2024

https://opencitations.net/index/api/v1/references/10.1211/0022357991772132

Identifiers

DOI

10.1211/0022357991772132

1 reference

23 July 2017

1 reference

PubMed ID

10217319